Latest Breaking News On - Norfolk quality - Page 4 : comparemela.com

Eplontersen continued to show improvement in ATTRv-PN through 85 weeks

Topline Phase 3 NEURO-TTRansform results show eplontersen continued to halt neuropathy disease progression and improve quality of life through 85 weeksData further strengthen eplontersen s.

Eugene schneiderDrug administrationExchange commissionIonis pharmaceuticals incIonis pharmaceuticalsPrnewswire ionis pharmaceuticals nasdaqTopline phaseNeuropathy impairment scoreNorfolk qualityLife questionnaire diabetic neuropathyNew drug applicationOrphan drug designationConjugated antisense

Ionis Pharmaceuticals, Inc (NASDAQ:IONS) Q1 2023 Earnings Call Transcript

Operator: Good morning, and welcome to Ionis First Quarter 2023 Financial Results Conference Call. As a reminder, this call is being recorded.

Paul matteisRichard gearyOnaiza cadoretKostas biliourisWilliam blairYanan zhuEric swayzeSalveen richterGena wangYaron werberTommie reerinkEugene schneiderBrendan smithJames condulisBeth hougenJessica fye

New Phase 3 Trial Data Show Eplontersen Improved Neuropathy in Over Half of Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Study shows eplontersen maintains a consistent and sustained treatment effect and reinforces its potential treating hereditary transthyretin-mediated amyloid polyneuropathy, which can lead to heart failure.

United statesYurii kibalnikSami khellaAmerican academy of neurologyIonis pharmaceuticalsPerelman school of medicineUniversity of pennsylvania school medicineEmerging science sessionAmerican academyPenn presbyterian medical centerClinical neurologyPerelman schoolPennsylvania schoolNeuropathy impairment scoreNorfolk qualityLife questionnaire diabetic neuropathy

Eplontersen Meets Co-Primary Endpoint in Phase 3 Trial for ATTRy-PN

The drug from AstraZeneca and Ionis Pharmaceuticals demonstrates a sustained benefit through 66 weeks for those with hereditary transthyretin-mediated amyloid polyneuropathy.

United statesSami khellaJacob lundIonis pharmaceuticalsPenn presbyterian medical centerAmerican academy of neurology annual meetingNeuropathy impairment scoreNorfolk qualityLife questionnaire diabeticAmerican academyNeurology annual meeting

AstraZeneca (AZN) Reports Eplontersen Demonstrated Sustained Benefit in Phase 3 Trial

AstraZeneca (AZN) Reports Eplontersen Demonstrated Sustained Benefit in Phase 3 Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesEugene schneiderSami khellaAmerican academy of neurology annual meetingDepartment of neurologyClinical developmentPenn presbyterian medical centerUniversity of pennsylvania school medicineDrug administrationNeuropathy impairment scoreNorfolk qualityLife questionnaire diabetic neuropathyClinical neurologyPennsylvania schoolExecutive vice presidentChief clinical development officer